FDA Accepts Aquestive’s Anaphylm Resubmission for Review

FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis. The Class 2 review has a target decision date of March 16, 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610150700PRIMZONEFULLFEED9846192) on October 15, 2026, and is solely responsible for the information contained therein. (C)